By Julia Karow

Complete Genomics said in a filing with the Securities and Exchange Commission last week that it has sold $14.49 million in securities.

CEO Cliff Reid told In Sequence by e-mail today that the amount raised in the sale represents "a portion" of the company's Series D financing, which is not yet complete. He declined to provide further details.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.